On June 27, 2025, Dyne Therapeutics, Inc. entered into a Loan Agreement with Hercules Capital for up to $275 million, with an initial $100 million tranche available immediately. This agreement includes various financial covenants and conditions involving the company’s cash levels and revenue requirements from its products.